Isabelle Danner‐Boucher

Rapid Improvement after Starting Elexacaftor–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease

Pierre‐Régis Burgel, I. Durieu, R. Chiron et al. · American Journal of Respiratory and Critical Care Medicine · 2021 · 235 citations

Medicine, Pharmacotherapy, Pulmonary Function Testing +15

High prevalence of triazole resistance in Aspergillus fumigatus, especially mediated by TR/L98H, in a French cohort of patients with cystic fibrosis

Florent Morio, Guillaume Ghislain Aubin, Isabelle Danner‐Boucher et al. · Journal of Antimicrobial Chemotherapy · 2012 · 124 citations

Life Sciences, Infectious Diseases, Microbiology +17

The French Compassionate Program of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del<i>CFTR</i>variant

Pierre‐Régis Burgel, Isabelle Sermet‐Gaudelus, I. Durieu et al. · European Respiratory Journal · 2023 · 85 citations

Medicine, Pharmacology, Pharmacotherapy +14

Disseminated <i>Scedosporium</i> / <i>Pseudallescheria</i> Infection after Double-Lung Transplantation in Patients with Cystic Fibrosis

Florent Morio, Delphine Horeau-Langlard, Françoise Gay‐Andrieu et al. · Journal of Clinical Microbiology · 2010 · 81 citations · Full text

Medicine, Infectious Diseases, Microbiology +17

Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis

Clémence Martin, Martine Reynaud‐Gaubert, Rébecca Hamidfar et al. · Journal of Cystic Fibrosis · 2022 · 65 citations

Medicine, Pharmacotherapy, Transplant Pharmacotherapy +12